Pembrolizumab

Phase 1/2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-muscle Invasive Bladder Cancer (NMIBC)

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Trial Timeline

Mar 2, 2018 → Jun 26, 2019

NCT ID

NCT03167151

About Pembrolizumab

Pembrolizumab is a phase 1/2 stage product being developed by Merck for Non-muscle Invasive Bladder Cancer (NMIBC). The current trial status is terminated. This product is registered under clinical trial identifier NCT03167151. Target conditions include Non-muscle Invasive Bladder Cancer (NMIBC).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02083484	Pre-clinical	Completed	—	—	Melanoma
NCT07302347	Phase 1/2	Recruiting	Mar 31, 2026	Dec 31, 2029	Malignant Neoplasm
NCT07089992	Phase 2	Recruiting	Dec 4, 2025	Dec 1, 2028	Sarcoma
NCT07007273	Phase 2	Recruiting	Jun 20, 2025	Jul 1, 2030	Cutaneous Sarcoma
NCT04569461	Phase 2	Withdrawn	Jun 1, 2025	Dec 1, 2026	Prostate Cancer
NCT05815927	Phase 3	Recruiting	May 23, 2025	Mar 30, 2030	Oligometastatic Squamous Cell Carcinoma of the Head and Neck
NCT05852223	Phase 2	Recruiting	Dec 20, 2024	Dec 1, 2027	Differentiated Thyroid Cancer
NCT05879120	Phase 2	Withdrawn	Jul 30, 2024	Oct 2, 2024	Recurrent Glioblastoma
NCT06004336	Phase 2	Recruiting	Oct 31, 2023	Jan 1, 2029	Oligometastatic Renal Cell Carcinoma
NCT05496036	Phase 2	Recruiting	Feb 13, 2023	Sep 30, 2027	Merkel Cell Carcinoma
NCT05131919	Phase 2	Active	Dec 22, 2022	Jul 1, 2031	Colorectal Cancer
NCT05197322	Phase 2	Recruiting	Jul 20, 2022	Dec 1, 2028	Adenocarcinoma of the Colon
NCT05406713	Phase 2	Active	Jul 13, 2022	Jan 1, 2028	Muscle Invasive Bladder Carcinoma
NCT05025813	Phase 2	Recruiting	Jun 28, 2022	Jun 1, 2027	Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT06413095	Phase 1	Completed	Jun 1, 2022	Jun 22, 2023	Head and Neck Squamous Cell Carcinoma
NCT05191472	Phase 2	Terminated	May 3, 2022	Dec 31, 2023	Multiple Myeloma
NCT05204160	Phase 2	Withdrawn	Apr 11, 2022	Feb 27, 2024	Plasma Cell Myeloma
NCT04575961	Phase 2	Active	Feb 22, 2022	Mar 1, 2028	Ovarian Cancer
NCT04417166	Phase 2	Recruiting	Feb 11, 2022	Dec 1, 2026	Lymphoma, Extranodal NK-T-Cell
NCT05188508	Phase 2	Recruiting	Jan 14, 2022	Jan 1, 2027	Glioma

Competing Products

18 competing products in Non-muscle Invasive Bladder Cancer (NMIBC)

See all competitors

Product	Company	Stage	Hype Score
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)	AstraZeneca	Phase 3	77
Durvalumab + BCG	AstraZeneca	Phase 3	77
Durvalumab + Monalizumab	AstraZeneca	Phase 2	52
Pembrolizumab + BCG	Merck	Phase 3	77
Sacituzumab tirumotecan + Rescue medication + Supportive care measures	Merck	Phase 1/2	41
Eciskafusp Alfa + BCG Medac Strain	Roche	Phase 1	33
PF-06801591 + Bacillus Calmette-Guerin	Pfizer	Phase 3	76
PF-08052667 + Sasanlimab + BCG + PF-02921367	Pfizer	Phase 1	32
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ) + BCG( 50mg/Instillation)	ImmunityBio	Phase 1/2	38
N-803 and BCG + N-803 and Gemcitabine	ImmunityBio	Phase 2	49
Cretostimogene Grenadenorepvec	CG Oncology	Phase 2	49
Cretostimogene Grenadenorepvec	CG Oncology	Pre-clinical	20
UGN-301 + UGN-201 + Gemcitabine	UroGen Pharma	Phase 1	28
AU-011	Aura Biosciences	Phase 1	25
TARA-002	Protara Therapeutics	Phase 1	25
TARA-002	Protara Therapeutics	Phase 2	44
TARA-002	Protara Therapeutics	Phase 1	25
PD-L1/IDO Peptide Vaccine + Pembrolizumab	IO Biotech	Phase 1	25

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved